Obinutuzumab for the treatment of podocytopathy with concurrent suspected but unconfirmed B-cell lymphoproliferative disorder: a case report and literature review

奥妥珠单抗治疗伴有疑似但未确诊的B细胞淋巴增殖性疾病的足细胞病:病例报告及文献综述

阅读:1

Abstract

B-lymphocyte proliferative disorder have a certain incidence rate among the elderly. Whether these conditions require treatment is closely related to the presence of concurrent organ damage. This case report details the diagnostic journey and treatment process of a 76-year-old male patient who presented with nephrotic syndrome and acute kidney injury. His condition was further complicated by the presence of monoclonal M proteinemia and the malignant B-lymphocytes in the bone marrow. Through a series of examinations, a diagnosis of podocytopathy with suspected but unconfirmed B-cell lymphoproliferative disorder was established. Treatment involved with CD20 monoclonal antibody (Obinutuzumab). The patient achieved complete remission of proteinuria and normalization of renal function within one month, sustained at one-year follow-up. While the underlying mechanism remains uncertain, whether direct immunomodulation, B-cell clone control or both. This is the first reported case of successful treatment of podocytopathy with concurrent suspected but unconfirmed B-cell lymphoproliferative disorder using Obinutuzumab, offering a new therapeutic way for similar complex medical conditions.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。